Sells body-contouring and tissue-treatment systems to cosmetic surgeons and hospitals, and develops electrosurgical equipment for medical-device makers.
Cosmetic-surgery customers buy Renuvion, AYON and J-Plasma; sales are generally counted when products ship or arrive under destination terms, with payment due under fixed terms. OEM makers buy generators, devices and accessories; most sales are counted at delivery, while qualifying made-to-order work is counted as it progresses.
10-K for FY2025, filed Mar 10, 2026Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the…View ↗
The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are…View ↗
OverviewView ↗
10-K for FY2025, filed Mar 10, 2026
FY2025 revenue by reportable segment ↗$52.8M
10-K for FY2025, filed Mar 10, 2026
$52.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Surgical Aesthetics
Sold outright
10-K for FY2025, filed Mar 10, 2026 |
86% |
Surgical Aesthetics, FY2025
$45.3M Sources
|
Sold outright |
|
OEM
Sold outright
10-K for FY2025, filed Mar 10, 2026 |
14%
FY2022: 17%
|
OEM, FY2025
$7.5M Sources
|
Sold outright |
In the U.S., physicians, cosmetic surgery offices and surgical centers buy Renuvion and AYON through Apyx's direct sales force; international sales mainly go through distributors. OEM customers include established medical-device makers and start-ups that need energy-based designs.
10-K for FY2025, filed Mar 10, 2026
Sales to one customer within the OEM segment represented 11% of sales for the year ended December 31, 2024.View ↗
No. It lost $11.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$1.8MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Jun 17, 2026
On June 11, 2026, Apyx Medical Corporation (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Stavros…View ↗
8-K, filed May 11, 2026
On May 11, 2026, Apyx Medical Corporation issued a press release announcing it received expanded 510(k) clearance from the U.S. Food and…View ↗
Growing. Revenue grew 9% in 4 years, from $48.5M in FY2021 to $52.8M in FY2025, about 2% a year.
AYON product line
The earlier report describes Renuvion and J-Plasma; the latest adds AYON, an all-in-one body-contouring system that combines fat removal, contouring and tissue contraction.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 10, 2026We are an advanced energy technology company with a passion for elevating people’s lives through innovative products, including our Helium…View ↗
China operations
The earlier report said the China joint venture had not started principal operations; the latest says it has begun operations and that Renuvion launched in China.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 10, 2026During late 2019, we entered into a joint venture with our Chinese supplier to establish a foundation for the manufacturing and sale of our…View ↗
Competes with Solta Medical and MicroAire Surgical Instruments
10-K for FY2025, filed Mar 10, 2026Currently, we are the only company with helium-based plasma products and four specific indications from the FDA. With the launch of AYON…View ↗
Loading...